Type 1 Diabetes Mellitus Clinical Trials in Miami, Florida

6 studies are recruiting for type 1 diabetes mellitus in Miami, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

   This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 393-days study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evalua…

   Stage

   Phase 1

   Ages

   12 to 35

   Site

   University of Miami, Miami, Florida

   Locations

   45 in total

   Run by

   COUR Pharmaceutical Development Company, Inc.

   See if you can join NCT06783309 on ClinicalTrials.gov

2. Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

   This Phase 2 study is a 2-arm, multi-center, double-masked (masking of the participant, care provider and investigator), placebo-controlled, 2:1 randomized trial design in new onset T1D participants (within 100 days of diagnosis). Participants will be administered rezpegaldesleukin/placebo once eve…

   Stage

   Phase 2

   Ages

   8 to 45

   Site

   University of Miami, Miami, Florida

   Locations

   15 in total

   Run by

   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

   See if you can join NCT07142252 on ClinicalTrials.gov

3. A Study of GNTI-122 in Adults Recently Diagnosed With T1D

   This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant's own blood cells in adult participants with recently diagnose…

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   University of Miami, Diabetes Research Institute, Miami, Florida

   Locations

   10 in total

   Run by

   GentiBio, Inc

   See if you can join NCT06919354 on ClinicalTrials.gov

4. Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

   This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.

   Stage

   Not phased

   Ages

   18 to 70

   Site

   Diabetes Research Institute, Miami, Florida

   Run by

   Rodolfo Alejandro

   See if you can join NCT01999361 on ClinicalTrials.gov

5. Long Term Follow up of Recipients of Functional Islet Allografts

   Since its inception, the Diabetes Research Institute (DRI) has made significant contributions to the field of diabetes, pioneering many of the techniques used in diabetes centers around the world. Through several clinical trials, DRI has demonstrated that diabetes can be successfully reversed as a …

   Stage

   Not phased

   Ages

   18 to 65

   Site

   Diabetes Research Institute, Miami, Florida

   Run by

   Rodolfo Alejandro

   See if you can join NCT01999374 on ClinicalTrials.gov

6. Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss

   This is a single-center, prospective, open label study in islet transplant recipients following islet graft loss.

   Stage

   Not phased

   Ages

   18 to 75

   Site

   Diabetes Research Institute, Miami, Florida

   Run by

   Rodolfo Alejandro

   See if you can join NCT02000687 on ClinicalTrials.gov